It is also the first drug approved for patients with primary progressive MS (PPMS), where symptoms get worse over time. In an interview with pharmaphorum, Marius Scholtz, country medical lead for ...

Roche is running three late-stage studies, namely FENhance 1 and 2 trials in relapsing MS, comparing the drug to Sanofi's Aubagio (teriflunomide) and the FENtrepid trial in primary progressive MS ...

Financial writer advises caution on Jyong Biotech Ltd. IPO due to high debt, legal issues, and FDA challenges. Click for my ...

Roche’s Evrysdi tablet receives US FDA approval for the treatment of spinal muscular atrophy: Basel Friday, February 14, 2025, 13:00 Hrs [IST] Roche, announced that the US Food ...

This is the medical term for difficulty with swallowing. It is common in conditions that affect the nervous system, including Parkinson’s disease. I ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

A groundbreaking study reveals how a rare combination of genetics, proteomics, and environmental factors may hold the key to ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle; Chief Operating Officer, Executive Vice President; Vertex Pharmaceuticals Inc Charles ...

relapsing-remitting MS active secondary progressive MS The drug comes as a solution for injection. The active ingredient in Briumvi is ublituximab-xiiy. Briumvi belongs to a group of drugs called ...